Tags : Tazemetostat

Epizyme Reports the US FDA Acceptance of NDA for Tazverik

Shots: The US FDA has accepted NDA for the accelerated approval of Tazverik for patients with relapsed/refractory FL prior treated with 2L+ systemic therapies The US FDA has granted PR and designated its NDA as sNDA. The sNDA is based on P-II study that demonstrated clinical benefits and was well tolerated in FL patients with […]Read More

Eisai to Transfer Royalty Rights for Tazemetostat to Royalty Pharma

Shots: Eisai to receive $110M upfront and $220M on marketing approval for tazemetostat in the US for certain indications and Royalty Pharma to get rights to receive royalties from Epizyme on sales outside of Japan In 2015, Epizyme and Eisai made amendment in their agreement for Tazemetostat candidate where Eisai will develop and commercialize in […]Read More